[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oesphageal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oesphageal-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100638875","mct-enteral-feeding-to-reduce-chyle-leak-after-oesophagectomy-100638875",false,"NCT07616245","MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of oesophageal cancer (adenocarcinoma or squamous cell carcinoma)\n* Planned minimally invasive or robotic-assisted oesophagectomy (MIO or RAMIO) with curative intent\n* Placement of feeding jejunostomy at or prior to oesophagectomy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* No feeding jejunostomy placed at or prior to surgery\n* Prior or concomitant malignancy that would interfere with study protocol or outcomes","ALL","18 Years",{"count":18,"type":19},160,"ESTIMATED","INTERVENTIONAL",[22],"NA","Chyle leak (chylothorax) is a recognised complication following minimally invasive oesophagectomy for oesophageal cancer and may result in prolonged hospital stay, nutritional compromise, and need for additional interventions.\n\nMedium-chain triglyceride (MCT) feeds reduce lymphatic flow as they are absorbed directly via the portal circulation rather than through the thoracic duct. While MCT feeds are commonly used in the management of established chyle leaks, their role in prevention has not been evaluated in a randomised controlled trial.\n\nThis single-centre randomised controlled trial will evaluate whether initiating postoperative jejunostomy feeding with MCT-based enteral nutrition reduces the incidence of clinically and biochemically confirmed chyle leak compared with standard enteral feeding in patients undergoing minimally invasive or robotic-assisted oesophagectomy.\n\nParticipants will be randomised in a 1:1 ratio to receive either MCT-based feeds or standard jejunostomy feeds starting on postoperative day 1. The primary outcome is the incidence of chylothorax. Secondary outcomes include chest drain output, re-intervention rates, and length of hospital stay.",[25],"Oesphageal Cancer",[27,28,29],"Robotic Oesophagectomy","Enhanced Recovery After Surgery","Oesphagectomy","RECRUITING","2026-05-29",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":34},"2025-10-02",{"date":38,"type":19},"2028-12-31",{"name":40,"class":41},"Royal College of Surgeons, Ireland","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100625761","the-pharo-trial-the-incidence-of-para-conduit-hernia-with-closure-of-hiatus-versus-the-standard-approach-in-robotic-oesophagectomy---a-randomised-controlled-pilot-trial-100625761","NCT07426835","The PHARO Trial: The Incidence of Para-conduit Hernia With Closure of Hiatus Versus the Standard Approach in Robotic Oesophagectomy - A Randomised Controlled Pilot Trial","PHARO","Inclusion Criteria:\n\nAge ≥ 18 years\n\nDiagnosis of oesophageal cancer\n\nPlanned robotic oesophagectomy with curative intent\n\nNo clinical or radiological evidence of distant metastases at time of recruitment\n\nAble to provide written informed consent\n\nExclusion Criteria:\n\nEvidence of distant metastatic disease\n\nNot suitable for robotic oesophagectomy\n\nInability to provide informed consent",{"count":51,"type":19},40,[22],"Para-conduit hernia is a recognised complication following minimally invasive and robotic oesophagectomy. It may present as an incidental radiological finding or as a symptomatic hernia requiring urgent surgical intervention. There is currently no standardised approach to hiatal management during robotic oesophagectomy.\n\nThe PHARO trial is a single-centre, randomised controlled pilot study evaluating whether routine hiatal closure with omentopexy and thoracic fixation of the left crus reduces the incidence of para-conduit hernia compared to the standard approach of no closure or partial closure.\n\nEligible patients undergoing robotic oesophagectomy for non-metastatic oesophageal cancer at Beaumont Hospital will be randomised in a 1:1 ratio to:\n\nStandard hiatal management (no closure or partial closure), or Hiatal closure with omentopexy and thoracic fixation of the left crus.\n\nParticipants will undergo routine postoperative clinical and radiological surveillance. The primary outcome is the incidence of para-conduit hernia within one year following surgery. Secondary outcomes include dysphagia scores, patient-reported outcomes, and 30-day postoperative morbidity.\n\nThis pilot study will enrol 40 participants (20 per group) to inform feasibility and future multi-centre expansion.",[25,55],"Para-conduit Hernia",[27,57,58,59,55,60,61,62,63],"Robot-Assisted Surgery","Hiatal Closure","Omentopexy","Minimally Invasive Oesophagectomy","Upper Gastrointestinal Surgery","Dysphagia","Edinburgh Dysphagia Score","2026-02-16",{"date":66,"type":34},"2026-02-23",{"date":68,"type":34},"2025-12-19",{"date":70,"type":19},"2029-12-31",{"name":40,"class":41}]